Melatonin for the prevention and treatment of cancer.
Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. · 2017
Read Melatonin for the prevention and treatment of cancer. by Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5503661.txt.
Introduction
Li and co-authors present a review in Oncotarget on melatonin against cancer. Melatonin is the hormone the pineal gland releases in darkness. It sets the body's daily clock. Population studies hint that it may also slow tumors. Lab work shows growth restraint in several tumor cell types.
The review gathers evidence across breast, prostate, stomach, and bowel cancers. Melatonin may act as an antioxidant and trigger cell death pathways. It can cut blood vessel growth and spread as well. Paired with standard therapy, it may boost gains and ease side effects. The authors call it a strong candidate for prevention work.
Catalog record
| CREATOR | Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 108 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Melatonin for the prevention and treatment of cancer By Ya Li, Sha Li, Yue Zhou, Xiao Meng, Jiao-Jiao Zhang, Dong-Ping Xu, Hua-Bin Li Published in: Oncotarget DOI: 10.18632/oncotarget.16379 ABSTRACT Abstract The epidemiological studies have indicated a possible oncostatic property of melatonin on different types of tumors. Besides, experimental studies have documented that melatonin could exert growth inhibition on some human tumor cells in vitro and in animal models. The underlying mechanisms include antioxidant activity, modulation of melatonin receptors MT1 and MT2, stimulation of apoptosis, regulation of pro-survival signaling and tumor metabolism, inhibition on angiogenesis, metastasis, and induction of epigenetic alteration. Melatonin could also be utilized as adjuvant of cancer therapies, through reinforcing the therapeutic effects and reducing the side effects of chemotherapies or radiation. Melatonin could be an excellent candidate for the prevention and treatment of several cancers, such as breast cancer, prostate cancer, gastric cancer and colorectal cancer. This review summarized the anticancer efficacy of melatonin, based on the results of epidemiological,experimental and clinical studies, and special attention was paid to the mechanisms of action. Keywords: melatonin, anticancer, mechanisms of action, receptor, apoptosis INTRODUCTION Melatonin (N-acetyl-5-methoxytryptamine, Figure 1) is an indolic compound secreted primarily by the pineal gland of human and mammals in response to darkness [1]. Except for the pineal, melatonin synthesis is also found in several other organs, including the retina, gastrointestinal tract, skin, bone marrow, and lymphocytes [2]. The process of melatonin biosynthesis and metabolism is shown in Figure 2, and only the primary metabolite 6-sulphatoxymelatonin (aMT6s) is included, because it is commonly used as the maker of circadian melatonin level [3–5]. The synthesis and secretion of melatonin are regulated by the ‘master biological clock’ located in the suprachiasmatic nucleus (SCN) of the hypothalamus [6]. Although melatonin is regulated by central circadian clock, it could also modulate central circadian clock and peripheral oscillators in tissues and organs, which makes melatonin a marker of circadian rhythms [7]. The melatonin level elevates at night and decreases throughout the day. Studies have shown that increased nighttime melatonin levels in the blood could send signals to the body's cells and organs that it is nighttime and help organize target organs and organ systems into appropriate homeostatic metabolic rhythms [8]. Therefore, light at night (LAN) could disrupt the circadian rhythm and the melatonin production [9], which could contribute to the development, promotion, and progression of cancers. [Figure: Structure of melatonin] [Figure: The biosynthesis and metabolism process of melatonin] According to the data reported by WHO, cancer is the leading cause of worldwide morbidity and mortality, with approximately 14 million new cases and 8.2 million cancer associated deaths in 2012 [10]. In the USA alone, it's estimated that in 2016, 1,685,210 new cancer cases and 595,690 cancer deaths could occur [11]. Nowadays, patients with cancer mainly count on clinical treatment, e.g. surgery, radiotherapy and chemotherapy. In addition, some natural products showed the potential for prevention and treatment of cancers [12–21]. Studies on cancer and anticancer therapies have attracted great attention. In the last decades, accumulating evidence has outlined the relevance of melatonin to human physiology and pathology. Now it is well accepted that melatonin is not only a hormone, but also a cell protector [22], involved in immunomodulation, antioxidative processes, and hematopoiesis [23, 24]. Moreover, a bunch of studies have shown that melatonin has important oncostatic properties, through receptor-dependent and receptor-independent mechanisms [25]. The melatonin receptors MT1 (encoded by MTNR1A) and MT2 (encoded by MTNR1B) belong to the G-protein-coupled receptor (GPCR) group [26], and are mainly responsible for mediating the downstream effects of melatonin [27]. For incidence, they are involved in inhibition of adenyl cyclase and cyclic AMP (cAMP), leading to a reduction in uptake of linoleic acid. Melatonin-induced inhibition on linoleic acid uptake is considered as a mechanism of its antiproliferative effects [28]. The receptor-independent mechanisms are associated with antioxidant activity, regulation of apoptosis, tumor metabolism and cancer immunity, inhibition on angiogenesis and migration, and prevention of circadian disruption [25, 29, 30]. Melatonin also showed the potential to be utilized as adjuvant of cancer therapies, through reinforcing the therapeutic effects and reducing the side effects of chemotherapies or radiation [31]. The objective of the present review is to summarize recent discoveries on the oncostatic property of melatonin, classified by hormone-dependent cancers and hormone-independent cancers, and to discuss the mechanisms of action, based on the results of epidemiological research, experimental studies and clinical trials. EPIDEMIOLOGICAL STUDIES Several epidemiological studies support a protective role of melatonin in cancer, yet not all the epidemiological studies are consistent (Table 1). Some studies suggested an inverse association between circadian melatonin level and breast cancer incidence. According to a dose-response analysis of observational studies, high artificial LAN exposure was related with an increased risk of breast cancer (RR = 1.17, 95% CI: 1.11-1.23), and risk of breast cancer was reduced by 14% with an increase of 15 ng/mg creatinine in urinary aMT6s (RR = 0.86, 95% CI: 0.78-0.95), with a linear dose-response trend (P-trend = 0.003) [32]. In addition, a case-control study found that female subjects with serum melatonin levels ≤ 39.5 pg/mL had a significantly higher risk of breast cancer incidence (about 15 folds) compared with subjects with levels > 39.5 pg/mL (OR = 14.24; 95% CI = 4.32-46.90). Meanwhile, the GG genotype of the MTNR1b (encoding melatonin receptor MT2) gene rs#10830963 polymorphism significantly elevated the risk of breast cancer by about 21 times more than the CC genotype (OR = 20.67; 95% CI = 4.77-99.33) [33]. Besides, a meta-analysis including 5 prospective case-control studies reported an inverse relationship between breast cancer risk and the highest levels of urinary aMT6s [34]. Another study evaluated the association between breast cancer risk and common single nucleotide polymorphismsin the MTNR1a, MTNR1b, and AANAT (encoding arylalkylamine N-acetyltransferase) genes among 2,073 cases and 2,083 controls, and reported that common genetic variation in the MTNR1a and MTNR1b genes might contribute to breast cancer susceptibility, and the associations might vary with menopausal status [27]. A nested case-control study reported that a higher urinary aMT6s level was significantly associated with a lower risk of breast cancer (OR = 0.62; 95% CI, 0.41-0.95; P(trend) = 0.004) [35]. However, 4 case-control studies suggested there was no evidence that melatonin level was associated with breast cancer risk. A prospective nested case-control study among British women pointed out that no statistically significant differences in urinary aMT6s level between women with breast cancer and healthy women were observed, regardless of menopausal status [36]. Besides, a case-control study nested in the Women's Health Initiative Observational Cohort reported there was no evidence that higher urinary levels of melatonin were inversely related with breast cancer risk in postmenopausal women [37]. Results from another case-control study nested within the Nurses' Health Study II cohort also did not support an overall association between urinary melatonin levels and breast cancer risk [38]. Likewise, no significant association was found between aMT6s level and breast cancer risk (either overall or by menopausal status) in a case-control study nested in the Guernsey III Study [39]. [Table: Epidemiological studies on melatonin level and cancer risks] As for cancers other than breast cancer, a case-cohort study reported that men with first morning urinary aMT6s levels below the median possessed a